NRSNHealthcare · BiotechnologyThe 3 Wall Street analysts covering Neurosense Therapeutics Ltd. hold a median 12-month price target of $7.5 — +1883.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Neurosense Therapeutics Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NRSN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1883.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | $14 |
| 25 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Mar 2026 | Roth Capital | Initiates | Buy | — |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 22 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 May 2025 | D. Boral Capital | Initiates | Buy | — |
| 16 Dec 2024 | Maxim Group | Downgrade | Hold | — |
| 17 July 2023 | Alliance Global Partners | Initiates | Buy | $7.50 |
| 7 Jan 2022 | Maxim Group | Initiates | Buy | $7.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRSN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 68% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neurosense Therapeutics Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeuroSense Therapeutics Ltd. issued a letter to shareholders on August 13, 2026, as announced in a press release from its Cambridge, Mass. headquarters.
Why it matters — A CEO letter to shareholders often provides updates on company strategy, milestones, or outlook, making it a key communication for NRSN watchers.
NeuroSense Therapeutics announced completion of the PrimeC pre-New Drug Submission (pre-NDS) process, with final meeting minutes confirming alignment with Health Canada on the planned content and structure of the ALS submission. The company is advancing toward filing with Health Canada in December 2026.
Why it matters — NRSN watchers would care because this regulatory milestone brings PrimeC closer to a formal Health Canada submission for ALS treatment, marking clear progress in the company's approval pathway.
The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. have a median 12-month price target of $7.5, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Neurosense Therapeutics Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurosense Therapeutics Ltd. 3 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Neurosense Therapeutics Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +1883.1% from the last close, and Ticker Nerd's factor model ranks Neurosense Therapeutics Ltd. 3 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neurosense Therapeutics Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRSN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.
Neurosense Therapeutics Ltd. returned -66.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases.
The most recent item we track (PRNewsWire, 13 Aug 2026): "NeuroSense Issues CEO Letter to Shareholders". NeuroSense Therapeutics Ltd. issued a letter to shareholders on August 13, 2026, as announced in a press release from its Cambridge, Mass. headquarters.
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases. Focusing primarily on targeting conditions like Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and Parkinson's disease, Neurosense leverages cutting-edge research to formulate therapeutic solutions that can address unmet medical needs. The company's research and development are rooted in a deep understanding of disease mechanisms, aiming to offer novel drug compounds that can alter the course of debilitating neurodegenerative disorders. Neurosense Therapeutics collaborates with academic institutions and research organizations to validate its scientific approaches, positioning itself as a significant player in the biotechnology sector. By advancing its drug candidates through rigorous clinical trials, the company aims to provide new hope for patients affected by these challenging diseases. Neurosense Therapeutics contributes to the global healthcare landscape by striving to deliver breakthroughs that could potentially improve quality of life for millions of patients worldwide.
CEO Mr. Alon Ben-Noon · 17 employees · Israel · https://www.neurosense-tx.com